NASDAQ · DXCM
DexCom, Inc.
Healthcare · Medical - Devices
$86.23▼ 0.07% ($0.06)at close
Pre-market$86.40▲ 0.20%7:10 AM ET
Market cap
$32.54B
P/E
33.80
EPS (TTM)
$2.55
Next earnings
Oct 29, 2026
Valuation
Revenue & margin DCF
Verdict: expensive. Price above all scenarios.
The price needs 23.1% revenue growth a year for 10 years. Our scenarios assume 7.1–12.3%.
That's 1.3× its past 4-year pace.
Value per share
Base case
$35.94
Price used $86.23 is 2.4× this
USD · TTM ending Jun 30, 2026 · Price Oct 1, 8:00 PM UTC
Revenue each value needs
Revenue today $5B. The price needs $39.8B by 2036. Base case: $12.7B. At its recent pace: $24.9B. Bear to Bull: $9.8B to $15.8B.
Revenue today $5B. The price needs $39.8B by 2036. Base case: $12.7B. At its recent pace: $24.9B. Bear to Bull: $9.8B to $15.8B.
Revenue in 2036
today $5B
+$27.2Bmore than the Base case · 3.1×
Value per share · Base case
$35.94
Price $86.23
2.4× this
- 10-yr revenue CAGR
- 9.8%
- Ending operating margin
- 25.9%
- Discount rate
- 12.6%
USD · TTM ending Jun 30, 2026 · Price Oct 1, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock rose 30.49% over the last year. Revenue grew 15.54% over the trailing twelve months. Operating margin moved from 15.98% to 22.92%. Free cash flow grew 146.15% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 12th percentile of their historical P/FCF range.
What would invalidate this read
Operating margin is at 22.92%. Revenue grew 15.54% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Return analysis
Company profile
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems.
Market multiples
Stock splits
Every 1 shares became 4
Profitability & growth
Analyst consensus
42
Buy
8
Hold
2
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Oct 29, 2026
Q3 FY26 · EPS est $0.67 · Revenue est $1.33B
View
Institutional Sentiment
DexCom, Inc. · DXCM
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.